Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings
pharmaphorum
AUGUST 2, 2022
The trial involved cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who were getting treatment with Tecentriq second-line after earlier platinum-based chemotherapy failed. Results from a trial in first-line NSCLC are due in early 2023.
105 
Let's personalize your content